Carcinotech

Success Story 06 August 2024

Edinburgh-based Carcinotech raised £4.2 million as part of its latest funding round and has plans to expand into the US. Using its Carcino3D technology, the startup creates 3D bioprinted tumor models using cancer cell lines derived from patients, providing a platform for rapid, ethical, and accurate drug screening, as well as pre-clinical and personalised medicine testing to support cancer treatment.

Region/Nation Scotland
Sector Life Sciences
Programme Investment Fund for Scotland
Partner
Photo of Carcinotech founder with fund manager Maven and British Business Bank

Eos Advisory (Eos) led the investment alongside Maven Capital Partners, Scottish Enterprise, Old College Capital, Investing Women, and existing investors TRICAPITAL, SIS Ventures, Gabriel Investment, and Alba Equity. The Maven investment of £750,000 is via the Investment Fund for Scotland, which Maven manages through Maven Equity Finance on behalf of the British Business Bank. 

Our vision is to be at the forefront of cancer drug testing and provide personalised medicine testing to every individual suffering from cancer to improve their treatment and chance of survival. Working with global partners, leading pharma companies, surgeons, pathologists, and clinicians, Carcinotech aims to significantly accelerate oncology drug development. - Ishani Malhotra CEO and Founder, Carcinotech